000			03389nam a22004815i 4500
001			u372521
003			SIRSI
005			20160812084102.0
007			cr nn 008mamaa
008			100722s2010 xxu| s |||| 0|eng d
020			_a9781603272711 _9978-1-60327-271-1
040			_cMX-MeUAM
050		4	_aRC261-271
082	0	4	_a614.5999 _223
100	1		_aPolunovsky, Vitaly A. _eeditor.
245	1	0	_amTOR Pathway and mTOR Inhibitors in Cancer Therapy _h[recurso electrónico] / _cedited by Vitaly A. Polunovsky, Peter J. Houghton.
264		1	_aTotowa, NJ : _bHumana Press : _bImprint: Humana Press, _c2010.
300			_aXII, 304 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aCancer Drug Discovery and Development
505	0		_amTORC1: A Signaling Integration Node Involved in Cell Growth -- The Regulation of the IGF-1/mTOR Pathway by the p53 Tumor Suppressor Gene Functions -- mTOR Signaling in Angiogenesis -- mTORC1 Signaling and Hypoxia -- mTOR Signaling in Glioblastoma: Lessons Learned from Bench to Bedside -- mTOR and Cancer Therapy: General Principles -- mTOR and Cancer Therapy: Clinical Development and Novel Prospects -- Drug Combinations as a Therapeutic Approach for mTORC1 Inhibitors in Human Cancer -- Downstream Targets of mTORC1 -- Downstream of mTOR: Translational Control of Cancer -- Genome-Wide Analysis of Translational Control -- Translational Control of Cancer: Implications for Targeted Therapy -- Downstream from mTOR: Therapeutic Approaches to Targeting the eIF4F Translation Initiation Complex.
520			_amTOR Pathway and mTOR Inhibitors in Cancer Therapy provides an up-to-date survey of the rapidly advancing field of cancer therapy. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment – targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. In this work, experts in TOR signaling have contributed in two thematic areas: mTOR Signaling and Cancer Therapy (chapters 1 - 8) and Therapeutic Targeting Downstream of mTOR (chapter 9 – 13). All chapters of mTOR Pathway and mTOR Inhibitors in Cancer Therapy are completely new or have been extensively updated by their authors; and we are indebted to all authors who have exemplified the links between these 2 thematic areas.
650		0	_aMedicine.
650		0	_aOncology.
650		0	_aToxicology.
650		0	_aCytology.
650	1	4	_aBiomedicine.
650	2	4	_aCancer Research.
650	2	4	_aCell Biology.
650	2	4	_aPharmacology/Toxicology.
700	1		_aHoughton, Peter J. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9781603272704
830		0	_aCancer Drug Discovery and Development
856	4	0	_zLibro electrónico _uhttp://148.231.10.114:2048/login?url=http://link.springer.com/book/10.1007/978-1-60327-271-1
596			_a19
942			_cLIBRO_ELEC
999			_c200401 _d200401